Rundu Pharmaceuticals Plans to Expand Nicotine Products Overseas

Jan.23

Investors inquire about potential collaboration with Swedish match company and US nicotine pouch sales for Ruando Group (002923.SZ).

Recently, an investor raised questions on the interactive platform asking whether Runto Corporation (002923.SZ) is collaborating with Swedish Match AB and whether they have plans to register their brand to sell nicotine pouch products in the United States.

In response to this, Runto Pharmaceuticals stated that the quality of the bioalkaloids (nicotine) produced by its wholly-owned subsidiary Runto Pharmaceuticals (Jingmen) Co., Ltd. has been widely recognized and has achieved commercial sales. Nicotine products can be applied in various fields such as pharmaceuticals, pesticides, e-cigarettes, nicotine pouches, and nicotine patches, with a wide range of applications. The company will actively understand the relevant domestic and foreign market access rules, strive to gain more commercial cooperation opportunities, and provide better returns for investors.

References:

[1] 公司有没有计划自己注册品牌在美国销售尼古丁袋产品？

Also Read:

[1] Production and Applications of Nicotine by Rundu International

[2] E-cigarette Company Rundu Stock's Performance and Roadshow

#Asia #China #Nicotine pouches #Major companies

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Special Report | Anti-Vaping Campaign in the Baltics Goes Sideways

2Firsts analyzes vaping regulations across the Baltic states. Following Latvia’s flavor ban, tax revenues fell and the black market expanded, while similar measures in Estonia and Lithuania have also failed to deliver results. The region’s anti-vaping policies are now triggering market imbalance and policy reassessment.

Oct.13

Bloomberg-Backed Campaign Wins as Denver Votes to Ban Flavored Nicotine

Denver voters have upheld the city’s ban on flavored nicotine products—including fruity vapes and menthol cigarettes—with 72% in favor during the Nov. 4 election. The “Yes on 310” campaign, backed by $5 million from Michael Bloomberg, celebrated the result as a major victory for youth health. Opponents, mostly local vape shop owners, warned of economic harm and called the spending imbalance unfair.

Nov.05 by 2FIRSTS.ai

JT Q3 2025: Revenue +18%, Profit +30%; RRP Volume +40%; Guidance Up

Japan Tobacco (JT) delivered a strong Q3 2025. Revenue rose 18.3% year over year to ¥947.2 billion, with adjusted operating profit up 27.8% to ¥279.0 billion (+20.8% at constant currency) and net profit up 29.7% to ¥176.7 billion. Growth was led by reduced-risk products (RRP): total RRP volume climbed 40%, with heated tobacco (HTS) up 53%. In Japan, the launches of Ploom AURA and EVO pods pushed HTS category share to 15.5%, while the Ploom user base has nearly doubled versus two years ago.

Oct.30 by 2FIRSTS.ai

Special Report｜With Charlie’s US Line Online, the US-Filled Vape Supply Chain Model Enters a New Phase

Charlie’s Holdings has activated its first US-based manufacturing and filling line, enabling the company’s Pachamama 25K vape series to meet Texas’ new domestic manufacturing requirements. As state-level rules tighten, the move signals a broader industry shift toward US-filled supply chains and marks an inflection point for brands historically reliant on China-based prefilled production.